Kisqali or Kryxana (Ribociclib)200mg x 21 Tablets

Product Description for Kisqali (Ribociclib) 200mg x 21 Tablets

Kisqali, also known by its generic name Ribociclib, is an oral medication used in combination with aromatase inhibitors for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) breast cancer in postmenopausal women. It is specifically indicated for use in combination with letrozole as initial endocrine-based therapy or with an aromatase inhibitor after progression on endocrine therapy.

How It Works

Kisqali works by inhibiting specific proteins (cyclin-dependent kinases 4 and 6) that are involved in cell division. By blocking these proteins, Kisqali helps to slow down or stop the growth of cancer cells. This targeted therapy is part of a comprehensive treatment strategy aimed at managing advanced breast cancer.

Dosage and Administration

The recommended dosage of Kisqali is 600 mg (three 200 mg tablets) taken once daily for 21 consecutive days, followed by 7 days off treatment. It is important to take Kisqali at the same time each day and to follow your healthcare provider's instructions carefully.

Possible Side Effects

Common side effects may include fatigue, nausea, vomiting, diarrhea, and decreased appetite. More serious side effects can occur, such as liver problems, low blood cell counts, and lung inflammation. Regular monitoring by a healthcare provider is essential to manage any potential adverse effects.

Drug Interactions

Kisqali can interact with other medications, which may affect how it works or increase the risk of serious side effects. Inform your healthcare provider about all medications you are currently taking, including over-the-counter drugs and supplements.

Important Information

Women who are pregnant or breastfeeding should not use Kisqali, as it may harm the fetus or nursing infant. Effective contraception is recommended during treatment and for at least 3 weeks after the last dose.

Conclusion

Kisqali represents a significant advancement in the treatment of HR-positive breast cancer, providing patients with a targeted therapy option. Always consult with your healthcare provider for personalized medical advice and to determine if Kisqali is the right choice for your treatment plan.